Pharmacokinetics of nevirapine: Once-daily versus twice-daily dosing in the 2NN study

HIV Clinical Trials

Volumn 6, Issue 5, 2005, Pages 254-261

  Kappelhoff, Bregt S ^a   Huitema, Alwin D R ^a   van Leth, Frank ^b   Robinson, Patrick A ^c   MacGregor, Thomas R ^c   Lange, Joep M A ^b   Beijnen, Jos H ^a,d  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

2NN; Nevirapine; Once daily; Pharmacokinetics; Twice daily

Indexed keywords

LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONLINEAR SYSTEM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; STEADY STATE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AREA UNDER CURVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MULTICENTER STUDIES; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE;

EID: 29744439524     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/B5VU-FU5F-QNWC-UDCK     Document Type: Article

References (26)

1. Murphy RL, Montaner J. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs. 1996;5(9):1183-1199.
2. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA. 1998;279(12):930-937.
3. Raffi F, Reliquet V, Ferre V, et al. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults. Antivir Ther. 2000;5(4):267-272.
4. Garcia F, Knobel H, Sambeat MA, et al. Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study. AIDS. 2000;14(16):2485-2494.
5. van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS. 2003;17(7):987-999.
6. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS. 1999;13(9):1099-1107.
7. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363:1253-1263.
8. Kappelhoff BS, Rosing H, Huitema ADR, Beijnen JH. Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;792(2):353-362.
9. Kappelhoff BS, van Leth F, MacGregor TR, et al. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther. 2005;10(1):145-155.
10. Beal S, Sheiner L. NONMEM User's Guides. NONMEM Project Group. San Francisco: University of California at San Francisco; 1998.
11. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150(9):1881-1884.
12. Goujard C, Bernard N, Sohier N, et al. Impact of a patient education program on adherence to HIV medication: a randomized clinical trial. J Acquir Immune Defic Syndr. 2003;34(2):191-194.
13. Hawkins T. Impact of once- and twice-daily dosing regimens on adherence and overall safety. AIDS Read. 2004;14(6):320-335.
14. Kappelhoff BS, van Leth F, Robinson PA et al. Are adverse events related with plasma concentrations of nevirapine and efavirenz? Antivir Ther. 2005;10(4):489-498.
15. van Leth F, Kappelhoff B, Johnson D, et al., and the 2NN Study group. Minimum plasma concentrations of nevirapine and efavirenz in relation to virologic failure in antiretroviral-naive patients. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston. Abstract 80.
16. van Heeswijk RPG, Veldkamp AI, Mulder JW, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS. 2000;14(8):F77-F82.
17. Veldkamp AI, Weverling GJ, Lange JMA, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS. 2001;15(9):1089-1095.
18. de Vries-Sluijs TE, Dieleman JP, Arts D, et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet. 2003;42(6):599-605.
19. Bonora S, Gonzalez de Requena D, Garazzino S, et al. Impact of nevirapine (NVP) trough concentrations (Ctrough) on time to achieve and time of maintenance of viral suppression (VS) in HIV+ patients taking NVP-based regimens. In: Program and abstracts of the 5th International Workshop on Clinical Pharmacology of HIV Therapy; April 1-3, 2004; Rome. Abstract 6.10.
20. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis. 1995;171(3):537-545.
21. Cheeseman SH, Hattox SE, McLaughlin MM, et al. Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother. 1993;37(2): 178-182.
22. Gonzalez de Requena D, Nunez M, Jimenez-Nacher I, Soriano V. Liver toxicity caused by nevirapine. AIDS. 2002;16(2):290-291.
23. de Maat MMR, ter Heine R, Mulder JW, et al. Incidence and risk factors for nevirapine-associated rash. Eur J Clin Pharmacol. 2003;59(5-6):457-462.
24. de Maat MMR, Mathôt RAA, Veldkamp AI, et al. Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals. Pharmacol Res. 2002;46(3):295-300.
25. Sarasa M, Miró JM, Knobel H, et al. Nevirapine plasma levels at two weeks neither predicts nevirapine-associated rash nor liver toxicity. In: Program and abstracts of the 5th International Workshop on Clinical Pharmacology of HIV Therapy; April 1-3, 2004; Rome. Abstract 6.5.
26. EMEA public statement on Viramune (nevirapine) - severe and life-threatening cutaneous and hepatic reactions (London, 12 April 2000, EMEA/11260/00). Available at: http://www.emea.eu.inf/pdfs/human/press/pus/1126000EN.pdf.